Claim and evidence Close ×
Insilico Medicine’s announcement of 8 July 2026 states that rentosertib, which it says was discovered and developed with the support of its generative AI platform, had entered a Phase III clinical trial. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Date 2026-07-08 · announcement Records dated 2026 → Role Articulation Register (kind of text) Nonfiction Scope of the passage A company announcement to the Hong Kong exchange; the phase is as stated. Scope and limits The record documents what this text states, in its register; it is not evidence that the proposition is true and implies no influence on or from any other text. The company’s own statement; no clinical-trial registry entry was retrieved. It rests on the same passages as the record of the company’s statement (recorded separately).
The evidence 02 primary source Supports the claim
InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial ↗ InSilico Medicine Cayman TopCo, published on HKEXnews · 2026-07-08
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “Rentosertib (ISM001-055), independently discovered and developed by Insilico Medicine, has officially entered Phase III clinical trial (CTR20262475, NCT07687459)” Location in source first paragraph
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors InSilico Medicine Cayman TopCo, published on HKEXnews Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 f3885577b28b14e540aa411ce2227da6bc3702b2bdfd64eb1c9c3beb41239c69). HKEXnews PDF 2026070800129, listed 2026-07-08, as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution InSilico Medicine Cayman TopCo, published on HKEXnews, “InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial”, 2026-07-08. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (18 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item B120) re-read the record’s sources and found full support. No human editorial review. primary source Supports the claim
InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial ↗ InSilico Medicine Cayman TopCo, published on HKEXnews · 2026-07-08
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “discovered and developed with the support of Insilico Medicine’s proprietary generative AI platform, Pharma. AI.” Location in source About Rentosertib
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors InSilico Medicine Cayman TopCo, published on HKEXnews Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 f3885577b28b14e540aa411ce2227da6bc3702b2bdfd64eb1c9c3beb41239c69). HKEXnews PDF 2026070800129, listed 2026-07-08, as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution InSilico Medicine Cayman TopCo, published on HKEXnews, “InSilico Medicine Cayman TopCo: Voluntary Announcement - Initiation of Insilico Medicine's Rentosertib Phase III Clinical Trial”, 2026-07-08. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (15 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item B120) re-read the record’s sources and found full support. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. A passage of the document meets the proposition’s criterion. The record documents what the text states, in its register (fiction and satire are labelled); it is not evidence that the proposition is true and implies no influence on or from another text.
Date. Date of the HKEXnews listing of the announcement.
Record ID aib-arg-p3-insilico-2026